期刊文献+

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

原文传递
导出
摘要 In the ARTEMIS-CTONG1509 multicenter phase 3 study recently published in Cancer Cell,Zhou et al.investigate the combination of the EGFR tyrosine kinase inhibitor(TKI)erlotinib and anti-angiogenic bevacizumab in treatmentnaive Chinese patients with advanced EGFR-mutant non-small cell lung cancer(NSCLC).^(1) The primary endpoint of progression-free survival(PFS)was significantly exte nded from 11.2 months with erloti nib mono therapy to 17.9 mon ths with the combination.
出处 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2022年第1期4-6,共3页 信号转导与靶向治疗(英文)
关键词 NSCLC TKI EGFR
  • 引文网络
  • 相关文献
;
使用帮助 返回顶部